Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2013 1
2017 2
2018 1
2019 8
2020 12
2021 17
2022 6
2023 4
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity.
Matsuda K, Migueles SA, Huang J, Bolkhovitinov L, Stuccio S, Griesman T, Pullano AA, Kang BH, Ishida E, Zimmerman M, Kashyap N, Martins KM, Stadlbauer D, Pederson J, Patamawenu A, Wright N, Shofner T, Evans S, Liang CJ, Candia J, Biancotto A, Fantoni G, Poole A, Smith J, Alexander J, Gurwith M, Krammer F, Connors M. Matsuda K, et al. Among authors: stadlbauer d. J Clin Invest. 2021 Mar 1;131(5):e140794. doi: 10.1172/JCI140794. J Clin Invest. 2021. PMID: 33529172 Free PMC article. Clinical Trial.
Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis.
Lee IT, Nachbagauer R, Ensz D, Schwartz H, Carmona L, Schaefers K, Avanesov A, Stadlbauer D, Henry C, Chen R, Huang W, Schrempp DR, Ananworanich J, Paris R. Lee IT, et al. Among authors: stadlbauer d. Nat Commun. 2023 Jun 19;14(1):3631. doi: 10.1038/s41467-023-39376-7. Nat Commun. 2023. PMID: 37336877 Free PMC article. Clinical Trial.
Human anti-N1 monoclonal antibodies elicited by pandemic H1N1 virus infection broadly inhibit HxN1 viruses in vitro and in vivo.
Hansen L, McMahon M, Turner HL, Zhu X, Turner JS, Ozorowski G, Stadlbauer D, Vahokoski J, Schmitz AJ, Rizk AA, Alsoussi WB, Strohmeier S, Yu W, Choreño-Parra JA, Jiménez-Alvarez L, Cruz-Lagunas A, Zúñiga J, Mudd PA, Cox RJ, Wilson IA, Ward AB, Ellebedy AH, Krammer F. Hansen L, et al. Among authors: stadlbauer d. Immunity. 2023 Aug 8;56(8):1927-1938.e8. doi: 10.1016/j.immuni.2023.07.004. Epub 2023 Jul 27. Immunity. 2023. PMID: 37506693
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial.
Nachbagauer R, Feser J, Naficy A, Bernstein DI, Guptill J, Walter EB, Berlanda-Scorza F, Stadlbauer D, Wilson PC, Aydillo T, Behzadi MA, Bhavsar D, Bliss C, Capuano C, Carreño JM, Chromikova V, Claeys C, Coughlan L, Freyn AW, Gast C, Javier A, Jiang K, Mariottini C, McMahon M, McNeal M, Solórzano A, Strohmeier S, Sun W, Van der Wielen M, Innis BL, García-Sastre A, Palese P, Krammer F. Nachbagauer R, et al. Among authors: stadlbauer d. Nat Med. 2021 Jan;27(1):106-114. doi: 10.1038/s41591-020-1118-7. Epub 2020 Dec 7. Nat Med. 2021. PMID: 33288923 Clinical Trial.
Antibody responses to influenza A(H1N1)pdm infection.
Wraith S, Nachbagauer R, Balmaseda A, Stadlbauer D, Ojeda S, Rajabhathor A, Lopez R, Guglia AF, Sanchez N, Amanat F, Gresh L, Kuan G, Krammer F, Gordon A. Wraith S, et al. Among authors: stadlbauer d. Vaccine. 2020 Jun 2;38(27):4221-4225. doi: 10.1016/j.vaccine.2020.04.069. Epub 2020 May 7. Vaccine. 2020. PMID: 32389495 Free PMC article.
Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: Results from the IMPACC study.
Ozonoff A, Schaenman J, Jayavelu ND, Milliren CE, Calfee CS, Cairns CB, Kraft M, Baden LR, Shaw AC, Krammer F, van Bakel H, Esserman DA, Liu S, Sesma AF, Simon V, Hafler DA, Montgomery RR, Kleinstein SH, Levy O, Bime C, Haddad EK, Erle DJ, Pulendran B, Nadeau KC, Davis MM, Hough CL, Messer WB, Higuita NIA, Metcalf JP, Atkinson MA, Brakenridge SC, Corry D, Kheradmand F, Ehrlich LIR, Melamed E, McComsey GA, Sekaly R, Diray-Arce J, Peters B, Augustine AD, Reed EF, Altman MC, Becker PM, Rouphael N; IMPACC study group members. Ozonoff A, et al. EBioMedicine. 2022 Sep;83:104208. doi: 10.1016/j.ebiom.2022.104208. Epub 2022 Aug 8. EBioMedicine. 2022. PMID: 35952496 Free PMC article.
SARS-CoV-2 spike E484K mutation reduces antibody neutralisation.
Jangra S, Ye C, Rathnasinghe R, Stadlbauer D; Personalized Virology Initiative study group; Krammer F, Simon V, Martinez-Sobrido L, García-Sastre A, Schotsaert M. Jangra S, et al. Among authors: stadlbauer d. Lancet Microbe. 2021 Jul;2(7):e283-e284. doi: 10.1016/S2666-5247(21)00068-9. Epub 2021 Apr 7. Lancet Microbe. 2021. PMID: 33846703 Free PMC article. No abstract available.
IgM N-glycosylation correlates with COVID-19 severity and rate of complement deposition.
Haslund-Gourley BS, Woloszczuk K, Hou J, Connors J, Cusimano G, Bell M, Taramangalam B, Fourati S, Mege N, Bernui M, Altman MC, Krammer F, van Bakel H; IMPACC Network; Maecker HT, Rouphael N, Diray-Arce J, Wigdahl B, Kutzler MA, Cairns CB, Haddad EK, Comunale MA. Haslund-Gourley BS, et al. Nat Commun. 2024 Jan 9;15(1):404. doi: 10.1038/s41467-023-44211-0. Nat Commun. 2024. PMID: 38195739 Free PMC article.
53 results